Cutting-Edge Breast Cancer Treatment and Clinical Research in Shanghai
For international patients seeking not only the best available standard-of-care treatment but also access to the latest clinical trials and emerging therapies, Fudan University Shanghai Cancer Center (FUSCC) offers one of China's most active breast cancer research programs. Prof. Qin Wenxing represents the next generation of China's breast oncology leadership — a nationally recognized young expert who is simultaneously shaping national guidelines and leading international clinical research.
Featured Specialist: Prof. Qin Wenxing (秦文星)
Prof. Qin Wenxing is a breast oncologist at Fudan University Shanghai Cancer Center (FUSCC), with clinical presence across both the main Shanghai campus and the Xiamen branch campus — extending FUSCC's world-class expertise to patients in southeastern China and beyond.
Prof. Qin is the recipient of the prestigious "Guozhi Mingyi · Qingnian Xinrui" Award (国之名医·青年新锐) — one of China's highest honors for outstanding young medical talent. He is a contributing author of the CSCO Breast Cancer Diagnosis and Treatment Guidelines — the national standard followed by oncology centers across China — and serves as principal investigator on multiple domestic and international clinical trials.
Comprehensive Breast Cancer Treatment
Prof. Qin's clinical expertise spans the full spectrum of breast cancer management, with particular strength in integrating the latest evidence into individualized treatment plans:
Early-Stage Breast Cancer
- Neoadjuvant chemotherapy optimization to maximize pathological complete response (pCR)
- Coordination of surgery timing with systemic therapy response
- Adjuvant therapy selection based on molecular subtype, genomic risk, and residual disease
- Post-neoadjuvant escalation strategies (T-DM1 for HER2+ residual disease; capecitabine for TNBC residual disease)
HER2-Positive Breast Cancer
- Dual HER2 blockade (trastuzumab + pertuzumab) with chemotherapyT-DM1 and T-DXd (trastuzumab deruxtecan) for residual or metastatic HER2+ disease
- Tucatinib-based regimens for HER2+ brain metastases
- HER2-low breast cancer — emerging treatment with T-DXd for patients previously classified as HER2-negative
Hormone Receptor-Positive Breast Cancer
- CDK4/6 inhibitor combinations for advanced HR+ disease
- ESR1 mutation monitoring and endocrine therapy sequencing
- Genomic testing (Oncotype DX, MammaPrint) to guide adjuvant chemotherapy decisions
- Extended adjuvant endocrine therapy planning for high-risk patients
Triple-Negative Breast Cancer
- Immunotherapy combinations (PD-1/PD-L1 inhibitors) for eligible patients
- PARP inhibitors for BRCA-mutated TNBC
- Fudan Classification-guided individualized therapy in collaboration with FUSCC colleagues
- Antibody-drug conjugates (sacituzumab govitecan) for refractory TNBC
Clinical Research and Trial Access
One of the most significant advantages of consulting Prof. Qin is access to FUSCC's extensive portfolio of active clinical trials. As a principal investigator on multiple domestic and international studies, Prof. Qin can offer eligible patients:
- Access to novel agents not yet commercially available in China or internationally
- Participation in international multi-center trials that place FUSCC patients alongside those at leading Western cancer centers
- Access to biomarker-driven basket trials for patients with specific molecular alterations
- Enrollment in post-neoadjuvant escalation studies for patients with residual disease after chemotherapy
- Participation in HER2-low and HER2-ultralow trials exploring the expanding HER2-targeted treatment landscape
CSCO Guidelines: Shaping National Standards
As a contributing author of the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines, Prof. Qin is directly involved in defining the evidence-based treatment standards used by oncologists across China. This means patients treated by Prof. Qin receive care that is not only aligned with current national guidelines but informed by the expert who helped write them — and who is actively updating them as new evidence emerges.
FUSCC Xiamen: Expanded Access
Prof. Qin's clinical presence at the FUSCC Xiamen branch campus means that patients in southeastern China, Taiwan, and Southeast Asia have an additional access point to FUSCC's world-class breast oncology expertise — without traveling to Shanghai. CMCS can coordinate consultations at either campus based on patient location and preference.
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We connect international patients with Shanghai's leading breast oncologists, including Prof. Qin Wenxing at Fudan University Shanghai Cancer Center, and manage every step of the process:
- Review of existing pathology, molecular profiling, and treatment history
- Clinical trial eligibility screening based on current FUSCC trial portfolio
- Appointment scheduling at FUSCC Shanghai or Xiamen campus
- Medical interpretation during consultations and tumor board discussions
- Coordination of additional molecular testing (NGS, HER2 re-testing, ESR1) if needed
- Logistics support: accommodation, visa assistance, and local transport
- Post-consultation follow-up and remote monitoring coordination
Get in Touch
If you are seeking comprehensive breast cancer treatment or access to cutting-edge clinical trials in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comments